Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 8,453.0 | 6,018.0 | 6,797.0 | 7,604.0 | 6,845.0 | 7,518.0 | 8,139.0 | 11,578.0 |
| Revenue growth | 40.5% | -11.5% | -10.6% | 11.1% | -9.0% | -7.6% | -29.7% | 4.5% |
| Cost of goods sold | 6,678.0 | 4,918.0 | 5,415.0 | 5,840.0 | 5,194.0 | 6,000.0 | 6,405.0 | 9,659.0 |
| Gross profit | 1,775.0 | 1,100.0 | 1,382.0 | 1,764.0 | 1,651.0 | 1,518.0 | 1,734.0 | 1,919.0 |
| Gross margin | 21.0% | 18.3% | 20.3% | 23.2% | 24.1% | 20.2% | 21.3% | 16.6% |
| Selling, general and administrative | 851.0 | 775.0 | 786.0 | 789.0 | 759.0 | 772.0 | 791.0 | 974.0 |
| Research and development | 150.0 | 135.0 | 137.0 | 145.0 | 132.0 | 137.0 | 143.0 | 158.0 |
| EBITA | 978.0 | 508.0 | 539.0 | 888.0 | 745.0 | 680.0 | 729.0 | 658.0 |
| EBITA margin | 11.6% | 8.4% | 7.9% | 11.7% | 10.9% | 9.0% | 9.0% | 5.7% |
| Amortization of intangibles | 40.0 | 33.0 | 16.0 | 6.0 | 3.0 | 12.0 | 6.0 | 19.0 |
| EBIT | 938.0 | 475.0 | 523.0 | 882.0 | 742.0 | 668.0 | 723.0 | 639.0 |
| EBIT margin | 11.1% | 7.9% | 7.7% | 11.6% | 10.8% | 8.9% | 8.9% | 5.5% |
| Pre-tax income | 1,313.0 | 337.0 | 391.0 | 734.0 | 531.0 | 474.0 | 488.0 | 404.0 |
| Income taxes | 209.0 | 46.0 | -38.0 | 45.0 | 20.0 | 109.0 | 60.0 | 51.0 |
| Tax rate | 15.9% | 13.6% | | 6.1% | 3.8% | 23.0% | 12.3% | 12.6% |
| Earnings from continuing ops | 1,045.0 | 259.0 | 393.0 | 376.0 | 406.0 | 699.0 | 823.0 | 684.0 |
| Earnings from discontinued ops | | 775.0 | 169.0 | -39.0 | 230.0 | -8.0 | -302.0 | -8.0 |
| Net income | 1,045.0 | 1,034.0 | 562.0 | 337.0 | 636.0 | 691.0 | 521.0 | 676.0 |
| Net margin | 12.4% | 17.2% | 8.3% | 4.4% | 9.3% | 9.2% | 6.4% | 5.8% |
| |
| Diluted EPS | $1.58 | $0.39 | $0.57 | $0.52 | $0.56 | $0.98 | $3.35 | $2.78 |
| Shares outstanding (diluted) | 662.0 | 664.4 | 690.1 | 721.3 | 726.2 | 715.5 | 245.4 | 246.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|